Yale New Haven Hospital

Running trials

• Recruiting

  Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

  NCT07578116· Phase 3· Source

• Not yet recruiting

  COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"

  NCT07281027· Phase 3· Source

• Not yet recruiting

  Prospective Study to Evaluate the Clinical Utility of ctDNA Tumor Fraction (TF) for Detection of Estrogen Receptor 1 (ESR1) Mutations in (Human Epidermal Growth Factor Receptor) HR+/HER2- Metastatic Breast Cancer (MBC)

  NCT07910565· Source

• Not yet recruiting

  Cilostazol for Prevention of Recurrent Stroke Trial

  NCT07174414· Phase 3· Source

• Recruiting

  A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML

  NCT07751991· Phase 1· Source

• Recruiting

  Pulmonary Hypertension and Oxygen Saturation Targeting in Preterm Infants

  NCT06373289· Source

• Recruiting

  WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department

  NCT07558265· Source

• Not yet recruiting

  Effects of Exercise Prior to Radical Prostatectomy

  NCT07746414· Source

• Recruiting

  FORWARD: Functional Outcomes in Real-World Treatment And Revascularization of Non-dominant and Distal M2 Occlusions

  NCT07749170· Source

• Recruiting

  Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

  NCT07604571· Phase 1· Source

• Recruiting

  Skin Color Matching in Head and Neck Reconstructive Surgery

  NCT07431099· Source

• Recruiting

  Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

  NCT07527858· Phase 2· Source

• Recruiting

  Phase 1 Study of PF-08046033 in Advanced Solid Tumors

  NCT07519655· Phase 1· Source

• Recruiting

  Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

  NCT07421700· Phase 1/2· Source

• Recruiting

  Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome

  NCT07273838· Phase 2· Source

• Recruiting

  Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

  NCT07166406· Phase 3· Source

• Recruiting

  A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis

  NCT07291180· Source

• Recruiting

  Delay AvoIding Primary Evaluation for ThRombectomy of Acute StrokE Patients With Large Vessel OCclusion in the Angiography SuiTe

  NCT06825897· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Source

• Recruiting

  A Trial Comparing High-Flow Nasal Cannula Versus Noninvasive Ventilation on Reintubation and Post-Extubation Respiratory Failure in High-Risk Patients With Systolic Heart Failure

  NCT06671015· Source

• Recruiting

  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  NCT06982521· Phase 3· Source

• Recruiting

  Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

  NCT06958328· Phase 3· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

  NCT07090499· Phase 1· Source

• Active, not recruiting

  A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

  NCT07005128· Phase 3· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Source

• Active, not recruiting

  A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

  NCT06966453· Phase 1/2· Source

• Recruiting

  Digoxin In NASH (CODIN)

  NCT06588699· Phase 2· Source

• Recruiting

  Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

  NCT06784752· Phase 3· Source

• Recruiting

  A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

  NCT06941272· Phase 1/2· Source

• Active, not recruiting

  Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)

  NCT06898957· Phase 1· Source

• Recruiting

  Regulation of Brain Glucose Metabolism in Type 1 Diabetes

  NCT05317455· Early phase 1· Source

• Recruiting

  A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

  NCT06820463· Phase 2· Source

• Active, not recruiting

  Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

  NCT06814145· Phase 2· Source

• Recruiting

  Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  NCT06580314· Phase 3· Source

• Recruiting

  REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE

  NCT06777368· Source

• Recruiting

  StrokeNet Thrombectomy Endovascular Platform

  NCT06289985· Source

• Recruiting

  Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

  NCT06475989· Phase 3· Source

• Recruiting

  A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  NCT06667076· Phase 2· Source

• Active, not recruiting

  Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

  NCT06691984· Phase 3· Source

• Recruiting

  Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

  NCT06458712· Phase 1· Source

• Recruiting

  Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition

  NCT06094478· Source

• Active, not recruiting

  Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy

  NCT06453213· Phase 4· Source

• Recruiting

  Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  NCT06395103· Phase 1/2· Source

• Enrolling by invitation

  Long-term Safety and Tolerability of BHV-7000

  NCT06443463· Phase 2· Source

• Active, not recruiting

  Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

  NCT06169215· Phase 2· Source

• Recruiting

  Reversibility of Brain Glucose Transport in Type 2 Diabetes Mellitus (T2DM)

  NCT05776563· Source

• Recruiting

  A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

  NCT06481306· Phase 1/2· Source

• Recruiting

  Blood Pressure Variability and Ischemic Stroke Outcome

  NCT05756257· Source

• Recruiting

  Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging

  NCT05907629· Source

• Active, not recruiting

  Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

  NCT06211036· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Stroke10 recruiting
• Childhood cancers7 recruiting
• Colorectal cancer7 recruiting
• Lung cancer7 recruiting
• Metastatic breast cancer7 recruiting
• Prostate cancer7 recruiting
• Multiple myeloma5 recruiting
• Pancreatic cancer5 recruiting
• Head and neck cancer4 recruiting
• Acute myeloid leukemia3 recruiting
• Bladder cancer3 recruiting
• Epilepsy3 recruiting
• Gastric and esophageal cancer3 recruiting
• Heart failure3 recruiting
• Ovarian cancer3 recruiting
• Sarcoma3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Coronary artery disease2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• High blood pressure2 recruiting
• Liver and biliary tract cancer2 recruiting
• Lupus (SLE)2 recruiting
• Myasthenia gravis2 recruiting
• Psoriasis2 recruiting
• Psoriatic arthritis2 recruiting
• Rheumatoid arthritis2 recruiting
• Sjögren's disease2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• Triple-negative breast cancer2 recruiting
• Type 2 diabetes2 recruiting
• Ankylosing spondylitis1 recruiting
• Atrial fibrillation1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• COPD1 recruiting
• Crohn's disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Hodgkin lymphoma1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Kidney cancer1 recruiting
• Melanoma1 recruiting
• Multiple sclerosis1 recruiting
• Neuroblastoma1 recruiting
• Neuroendocrine tumours1 recruiting
• Obesity1 recruiting
• Parkinson disease1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Sickle cell disease1 recruiting
• Thyroid cancer1 recruiting
• Type 1 diabetes1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

  NCT06974734· Phase 1· Source

• Recruiting

  A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

  NCT06841354· Phase 3· Source

• Recruiting

  A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

  NCT06568939· Phase 2· Source

• Withdrawn

  A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)

  NCT06395090· Phase 1/2· Source

• Completed

  Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

  NCT06322342· Phase 2· Source

• Completed

  RECOVER-ENERGIZE Platform Protocol

  NCT06404047· Source

• Completed

  Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study

  NCT06111768· Phase 2· Source

• Completed

  A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

  NCT06188559· Phase 2· Source

• Completed

  A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

  NCT06280391· Phase 2· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Source

• Completed

  Long Term Follow Up KET-PD

  NCT06164756· Source

• Completed

  Tka Assay for CDK4/6i

  NCT06572800· Source

• Terminated

  Feasibility Study: tDCS for Treatment of Refractory Status Epilepticus

  NCT05934903· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

  NCT05767346· Phase 3· Source

• Terminated

  Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

  NCT05776875· Phase 2· Source

• Recruiting

  First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

  NCT05768139· Phase 1/2· Source

• Completed

  A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma

  NCT05376800· Phase 1· Source

• Completed

  A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants

  NCT05603312· Phase 1/2· Source

• Terminated

  First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies

  NCT05348889· Phase 1/2· Source

• Withdrawn

  Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amyloidosis in Medical Records

  NCT04569903· Early phase 1· Source

• Completed

  Use of Psychologist-administered Cognitive Behavioral Therapy (CBT) or Self-administered CBT for the Treatment of Anxiety and/or Depression in Inflammatory Bowel Disease (IBD)

  NCT05377840· Source

• Terminated

  A Study to Investigate LYL797 in Adults With Solid Tumors

  NCT05274451· Phase 1· Source

• Completed

  Ketamine for the Treatment of Depression in Parkinson's Disease

  NCT04944017· Phase 2· Source

• Completed

  Stimulation of the Thalamus for Arousal Restoral in Temporal Lobe Epilepsy

  NCT04897776· Source

• Completed

  A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

  NCT05076149· Phase 3· Source

• Withdrawn

  Reversibility of Brain Glucose Transport and Metabolism in T2DM: an Intervention Study

  NCT04283617· Source

• Completed

  Afrezza® INHALE-1 Study in Pediatrics

  NCT04974528· Phase 3· Source

• Completed

  Heart Watch Study: a Pragmatic Randomized Controlled Trial

  NCT04468321· Source

• Completed

  EXHIT ENTRE Comparative Effectiveness Trial

  NCT04345718· Phase 2/3· Source

• Completed

  Metabolic Changes Induced by a Very Low Carbohydrate Diet in Youth With Type 1 Diabetes

  NCT04955691· Source

• Completed

  Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3

  NCT04649229· Phase 4· Source

• Completed

  Yale COVID-19 Recovery Study

  NCT04895189· Source

• Completed

  A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)

  NCT04299464· Phase 2· Source

• Completed

  A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)

  NCT04495257· Phase 1· Source

• Terminated

  Blood PREssure Augmentation in Large-vessel Occlusion Stroke Study

  NCT04218773· Early phase 1· Source

• Completed

  PANDORA: Delirium Prevention After Cardiac Surgery Using IV Acetaminophen to Prevent Postoperative Delirium in Older Cardiac Surgical Patients

  NCT04093219· Phase 3· Source

• Completed

  Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

  NCT04321031· Phase 2· Source

• Completed

  Multi-arm Optimization of Stroke Thrombolysis

  NCT03735979· Phase 3· Source

• Completed

  Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

  NCT03971474· Phase 2· Source

• Completed

  Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer

  NCT03941093· Phase 3· Source

• Completed

  A Clinical Trial to Confirm Safety & Effectiveness of the SYNERGY 4.50 mm and 5.00 mm Stent for Treatment of Atherosclerotic Lesion(s)

  NCT03875651· Source

• Completed

  Sleep for Stroke Management and Recovery Trial

  NCT03812653· Source

• Completed

  Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT03845296· Phase 2· Source

• Completed

  Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

  NCT03768414· Phase 3· Source

• Completed

  Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer

  NCT03201458· Phase 2· Source

• Completed

  Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

  NCT03008278· Phase 1/2· Source

• Completed

  S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

  NCT03365882· Phase 2· Source

• Completed

  Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents

  NCT02936752· Phase 1· Source

• Completed

  Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

  NCT02568553· Phase 1· Source

• Completed

  Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer

  NCT02899793· Phase 2· Source

Trial sites

• Yale New Haven Hospital1 trial
• Smilow Cancer Center/Yale-New Haven Hospital94 trials
• Yale Cancer Center - Yale New Haven Hospital1 trial
• Yale New Haven Hospital101 trials
• Yale - New Haven Hospital / Cancer Center1 trial
• Yale New Haven Hospital (CICU or MICU)1 trial
• Yale New Haven Hospital /ID# 2466471 trial
• Yale New Haven Hospital /ID# 2705651 trial
• Yale New Haven Hospital /ID# 2715841 trial
• Yale New Haven Hospital, Saint Raphael Campus (MRE location)1 trial
• Yale New Haven Hospital (Site 0001)1 trial
• Yale New Haven Hospital (Site 1012)1 trial
• Yale New Haven Hospital (Site 1093)1 trial
• Yale-New Haven Hospital (Site 2012)1 trial
• Yale New Haven Hospital (Site 3012)1 trial
• Yale New Haven Hospital- Site Number : 84000651 trial
• Yale - New Haven Hospital - Yale Cancer Center15 trials
• Yale New Haven Hospital (YNHH) Research Unit (HRU)1 trial
• Yale New Haven Hospital - York Street Campus1 trial
• Yale School of Medicine - Yale-New Haven Hospital4 trials
• Yale University School of Medicine - Yale-New Haven Hospital1 trial
• Yale University - Yale New Haven Hospital4 trials
• Yale New Haven Hospital1 trial
• Yale-New Haven Hospital1 trial
• Yale-New Haven Hospital - Yale Cancer Center1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Long COVID and ME/CFS8 works · 2 trials